Antivenom ViperaTAb - BTG

Drug Profile

Antivenom ViperaTAb - BTG

Alternative Names: Common adder antivenom ViperaTAb - Protherics; ViperaTAb

Latest Information Update: 18 Jan 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protherics
  • Class Antivenins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Snake venom poisoning

Most Recent Events

  • 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum
  • 04 Dec 2008 Protherics has been acquired and merged into BTG
  • 24 Jun 2003 ViperaTAb is available for licensing in the EU (http://www.protherics.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top